Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.20
-0.19 (-0.75%)
Nov 5, 2024, 11:14 AM EST - Market open
Celldex Therapeutics Employees
Celldex Therapeutics had 160 employees as of December 31, 2023. The number of employees increased by 12 or 8.11% compared to the previous year.
Employees
160
Change (1Y)
12
Growth (1Y)
8.11%
Revenue / Employee
$51,894
Profits / Employee
-$938,850
Market Cap
1.67B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Myriad Genetics | 2,700 |
Certara | 1,391 |
AtriCure | 1,200 |
Galapagos NV | 1,123 |
Harrow | 315 |
Nurix Therapeutics | 284 |
Tarsus Pharmaceuticals | 244 |
Viridian Therapeutics | 94 |
CLDX News
- 20 hours ago - Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
- 9 days ago - Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - GlobeNewsWire
- 11 days ago - Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - GlobeNewsWire
- 5 weeks ago - Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - GlobeNewsWire
- 7 weeks ago - Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria - GlobeNewsWire